Drugs / DWJ1252
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01094847 | Apr → May 2010 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03184402 | Apr → Jul 2017 | dyspepsia | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT03024086 | Dec 2016 → Apr 2017 | dyspepsia | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWJ1252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03184402 ↗ |
| Route | Oral | “DWJ1252 given by oral administration under fasting conditions” NCT01094847 ↗ |